Detrusitol 2mg & 4mg Prolonged Release Capsule
PDF Leaflet Revision Date: 27 September 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of overactive bladder with urinary urgency, frequency, and/or urge incontinence.
Dosage (summary)
Adults: 4 mg once daily; may reduce to 2 mg based on tolerability. Impaired renal/hepatic function: 2 mg once daily.
Onset of Action / Duration
Onset: 2-6 hours, Duration: ~6 hours
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety not established; advise contraceptive cover.
Key Drug Interactions
- Anticholinergic drugs
- Cholinergic agonists
- CYP2D6 inhibitors (e.g., fluoxetine)
- CYP3A4 inhibitors (e.g., ketoconazole)
Contraindications
- Hypersensitivity to tolterodine
- Urinary retention
- Gastric retention
- Narrow angle glaucoma
- Myasthenia gravis
- Severe ulcerative colitis
- Toxic megacolon
Common side effects
- Dry mouth
- Dizziness
- Headache
- Constipation
- Dry eyes
Counselling Points
- Take with or without food
- Swallow capsules whole
- Monitor for urinary retention symptoms
Serious warnings
- Risk of urinary retention
- Caution in glaucoma
- QT prolongation risk
Important Disclaimer
The Detrusitol 2mg & 4mg Prolonged Release Capsule professional information leaflet below is the property of Viatris Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
